Introduction:

Induction chemotherapy serves as the cornerstone of treatment for Acute Myeloid Leukemia (AML), aiming to induce disease remission by eradicating leukemic blasts in the bone marrow. This article provides an overview of induction chemotherapy protocols, their efficacy, and associated considerations in managing AML.

Goals of Induction Chemotherapy:

The primary objectives of induction chemotherapy in AML are:

• Achievement of Remission: Induction therapy aims to eliminate leukemic blasts from the bone marrow and peripheral blood, leading to morphological remission and resolution of clinical symptoms.
• Prolongation of Remission: Induction chemotherapy sets the stage for subsequent consolidation therapy or stem cell transplantation, aiming to prevent disease relapse and prolong survival.

Standard Induction Chemotherapy Regimens:

Several induction chemotherapy regimens are employed in the treatment of AML:

• 7+3 Regimen: The "7+3" regimen consists of cytarabine (Ara-C) given as a continuous infusion for seven days, combined with an anthracycline (such as daunorubicin or idarubicin) administered as an intravenous infusion for three days. This regimen is considered the standard of care for younger, fit AML patients.
• Hypomethylating Agents: In older or medically unfit AML patients, hypomethylating agents such as azacitidine or decitabine may be used as induction therapy. These agents exert their antileukemic effects by reversing abnormal DNA methylation patterns and inducing differentiation of leukemic blasts.

Considerations in Induction Chemotherapy:

Several factors influence the choice and administration of induction chemotherapy in AML:

• Patient Age and Performance Status: Treatment decisions are tailored based on patient age, overall health status, comorbidities, and functional status. Younger, fit patients may tolerate intensive chemotherapy regimens, whereas older or medically unfit patients may benefit from less intensive approaches.
• Cytogenetic and Molecular Risk Stratification: Cytogenetic and molecular profiling of AML informs risk stratification and treatment selection. Patients with favorable-risk cytogenetics (such as t(8;21) or inv(16)) may achieve favorable outcomes with standard induction chemotherapy, whereas those with adverse-risk cytogenetics or mutations (such as FLT3-ITD or TP53 mutations) may require alternative treatment strategies.
• Response Assessment: Monitoring response to induction chemotherapy involves assessing peripheral blood counts, bone marrow aspirate and biopsy, and molecular or cytogenetic analyses. Complete remission (CR) is defined by the absence of peripheral blood blasts, less than 5% blasts in the bone marrow, and recovery of hematopoiesis.

Supportive Care During Induction Therapy:

Supportive care measures are essential to manage treatment-related toxicities and minimize complications during induction chemotherapy:

• Infection Prophylaxis: Prophylactic antibiotics, antifungals, and antivirals are administered to prevent infections, particularly in neutropenic patients at risk for bacterial, fungal, or viral pathogens.
• Transfusion Support: Red blood cell and platelet transfusions are provided to manage anemia and thrombocytopenia, respectively, during induction therapy, reducing the risk of bleeding and improving patient comfort.
• Growth Factor Support: Granulocyte colony-stimulating factors (G-CSF) such as filgrastim or pegfilgrastim may be used to accelerate neutrophil recovery and reduce the duration of neutropenia following induction chemotherapy.

Conclusion:

Induction chemotherapy is a crucial component of AML treatment, aiming to achieve disease remission and pave the way for subsequent therapies. Tailored induction regimens, supportive care interventions, and vigilant response monitoring are essential in optimizing outcomes and improving survival in AML patients.

Hashtags: #AcuteMyeloidLeukemia #AML #InductionChemotherapy #Remission #SupportiveCare